Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Microscopy of living cancer cells at physiological oxygen levels: the MICROX platform

Project description

Microscopy at physiological oxygen levels

Drug research and development is replacing standard plate-reader assays with microscopy screening. Combined with innovative functional assays, it is possible to monitor dynamic events in living cells. The EU-funded MICROX will work on microscopy-assays that resemble the real oxygen levels that our cells encounter. Conventional protocols maintain cells at 21 % oxygen, whereas physiologically most cells are exposed to 2-5 % oxygen and cancer cells to hypoxic conditions. The resultant MICROX microscopy platform will offer the capacity to adjust atmospheric conditions according to cell type, and importantly, facilitate the discovery and screening of anticancer drugs.

Objective

Functional evaluation of bioactive compounds using cell-based assays is key in discovering new and improved drugs to address our societies growing medical needs. In a large number of academic and private R&D facilities around the world, hi-content microscopy screening is used to complement and often outperform the conventional luminescence and fluorescence plate-reader assays. The combination of fluorescent-probe technology, modern optical microscopes and innovative functional assays allows monitoring highly dynamic events in living cells with exquisite temporal and spatial resolution.
Remarkably, drug candidates and treatment regimens are commonly tested on living cells maintained at atmospheric oxygenation levels (i.e. at 21% O2) while in reality, cells in our bodies never experience such high oxygen levels. Rather, most cells experience 2-5% of O2 and cancer cells in solid tumours are generally hypoxic, i.e. they function at < 1% of O2. It has become evident that oxygenation of the preparation dramatically affects efficacy of our drugs, in particular of cancer treatments. Thus, there is an urgent need to establish functional microscopy assays for (cancer)drug efficacy at hypoxic conditions.
However, it is not trivial to enclose the necessary high-end microscopes in O2-tight incubators while maintaining good access to the cells. In this project, experienced biochemist and pharmacologist dr. Olga Mazina aims to team up with the advanced microscopy group of prof. Kees Jalink to establish an innovative MICROX microscopy platform with fully adjustable atmospheric conditions, along with a panel of biosensors optimized for use at hypoxia. MICROX will be developed in close collaboration with leading European manufacturers and validated in studies addressing cancer cell signalling and sensitivity to cancer drugs at various O2 levels.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF-EF-CAR - CAR – Career Restart panel

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 281 358,72
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 281 358,72
My booklet 0 0